← Leaderboards
Brandon Smaglo
Marker Therapeutics, Inc.
$674,275
Attributed
$1,348,550
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $674.3K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,348,550 · 1
By mechanism
R44$1,348,550 · 1
Top collaborators
- Juan Fernando Vera2 shared
Most similar at Marker Therapeutics, Inc.
Same institution · by research overlap
- Juan Fernando Vera$7,624,284
- Laura S Angelo$997,257
Others in their field
Other Rising Stars on “Antigens”
- Jason Dickens · Duke University$12,259,409
- Warwick Britton · University Of Sydney$10,964,476
- Suma Babu · Massachusetts General Hospital$9,673,541
- Sabrina Paganoni · Massachusetts General Hospital$9,673,541
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Philip Felgner · University Of California-Irvine$9,134,165
Research focus
AntigensAntigen-Specific T CellsAutologousBiologicalBiological ProductsBiologic CharacteristicBlood Component RemovalCancer CellCancer ControlCancer TypeCd4 Positive T LymphocytesCd8b1 GeneCd8-Positive T-LymphocytesCell KillingCellsCell TherapyCharacteristicsChemotherapyClinical DataClinical EfficacyClinical ProtocolsClinical ResearchClinical TrialsAdvanced Disease
Grant awards (2)
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674,275
R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674,275
R44 · FY2024 · CA